A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Phase 2 Unknown 46 enrolled Yi Luo

NaSingle-groupOpen-labelPrevention

A single-arm trial using Tocilizumab for acute GVHD prophylaxis after haploidentical HSCT.

Evaluation	Drug	Modality	Dose	Route
Subject	Tocilizumab	Monoclonal antibody	8 mg/kg	Intravenous
Background	Busulfan	Small molecule	3.2 mg/kg	Intravenous
Background	Cyclophosphamide	Other / unclassified	1.8 g	Intravenous
Background	Cyclosporine	Peptide	2.5 mg/kg	Intravenous
Background	Cytarabine	Small molecule	4 mg/m2	Intravenous
Background	MTX	Unknown	10 mg/m2	Intravenous
Background	Me-CCNU	Unknown	250 mg/m2	Oral
Background	Mycophenolate Mofetil	Small molecule	500 mg	Intravenous
Background	Thymoglobulin	Protein / enzyme biologic	1.5 mg/kg	Intravenous